All In Biotech

Drug Trial Radar · NCT06361108

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

A Phase I, Randomized, Double-Blind, Placebo Controlled MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of Topical Application of YJ001 for Spray Use in Patients With DPNP

Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

May 16, 2024

Primary completion

Dec 20, 2025

Study completion Jun 30, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP. The study will be conducted at a single study center. In this study, 2 cohorts (N=24, 12 subjects for each cohort), each cohort will consist of 10 active and 2 placebo, with approximately equal numbers of male and female subjects. Each subject will be administered a single dose of YJ001 as multiple sprays topically on both feet and below the ankle in the morning on Day 1 and Day 2, and will be administered as twice daily doses once in the morning and the other in the evening (with an interval of 11 to 13 h) from Day 3 through Day 11.

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

  • YJ001 for Spray UseDrug

    Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)

  • Placebo of YJ001 for Spray UseDrug

    Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Assessments - AEsTime frame: through study completion, an average of 1year
  2. Safety Assessments -Number of Participants With Abnormal Laboratory ValuesTime frame: through study completion, an average of 1year
  3. Safety Assessments - Skin ReactionTime frame: through study completion, an average of 1year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trials of Texas,LLC

    Fredericksburg, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.